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Background
Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates 
thrombopoiesis. We evaluated its ability to increase platelet counts and facilitate 
treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia 
associated with HCV-related cirrhosis.
Methods
Seventy-four patients with HCV-related cirrhosis and platelet counts of 20,000 to 
less than 70,000 per cubic millimeter were randomly assigned to receive eltrombopag 
(30, 50, or 75 mg daily) or placebo daily for 4 weeks. The primary end point was a 
platelet count of 100,000 per cubic millimeter or more at week 4. Peginterferon and 
ribavirin could then be initiated, with continuation of eltrombopag or placebo for 
12 additional weeks.
Results
At week 4, platelet counts were increased to 100,000 per cubic millimeter or more 
in a dose-dependent manner among patients for whom these data were available: 
in 0 of the 17 patients receiving placebo, in 9 of 12 (75%) receiving 30 mg of eltrombo-
pag, in 15 of 19 (79%) receiving 50 mg of eltrombopag, and in 20 of 21 (95%) receiv-
ing 75 mg of eltrombopag (P<0.001). Antiviral therapy was initiated in 49 patients 
(in 4 of 18 patients receiving placebo, 10 of 14 receiving 30 mg of eltrombopag, 14 of 
19 receiving 50 mg of eltrombopag, and 21 of 23 receiving 75 mg of eltrombopag) 
while the administration of eltrombopag or placebo was continued. Twelve weeks 
of antiviral therapy, with concurrent receipt of eltrombopag or placebo, were com-
pleted by 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, and 75 mg of 
eltrombopag, respectively, and by 6% of patients in the placebo group. The most 
common adverse event during the initial 4 weeks was headache; thereafter, the ad-
verse events were those expected with interferon-based therapy.
Conclusions
Eltrombopag therapy increases platelet counts in patients with thrombocytopenia 
due to HCV-related cirrhosis, thereby permitting the initiation of antiviral therapy. 
(ClinicalTrials.gov number, NCT00110799.)
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
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Thrombocytopenia is a frequent complication of chronic liver disease and is considered an indicator of advanced dis-
ease.1-3 The low platelet count is due partly to the 
effects of portal hypertension and hypersplen-
ism,4 decreased thrombopoietin production,2,5,6 
and virus-induced bone marrow suppression.7,8
Patients with chronic liver disease due to in-
fection with the hepatitis C virus (HCV) who have 
thrombocytopenia (<75,000 platelets per cubic 
millimeter) have been routinely excluded from 
clinical trials of interferon and ribavirin, and few 
published reports have described the treatment of 
chronic HCV infection in patients with platelet 
counts of less than 50,000 per cubic millimeter. 
Although a reduced platelet count is not an abso-
lute contraindication to treatment with pegylated 
interferon (peginterferon) and ribavirin, product la-
bels advise that caution be used in treating patients 
with clinically significant thrombocytopenia. Fur-
thermore, if thrombocytopenia develops during 
antiviral therapy, peginterferon may need to be 
delivered at a reduced dose or discontinued.9,10 
Currently, there is no approved treatment for throm-
bocytopenia in patients with HCV infection.
Eltrombopag (SB-497115, GlaxoSmithKline) is 
a new, small-molecule, nonpeptide, oral platelet 
growth factor that acts as a thrombopoietin-recep-
tor agonist. The drug interacts with the trans-
membrane domain of the thrombopoietin recep-
tor and induces proliferation and differentiation 
of megakaryocytes and, as a result, an increase in 
platelet production. In preclinical and early clini-
cal studies, eltrombopag therapy was shown to 
stimulate megakaryocyte proliferation and differ-
entiation and to cause dose-dependent increases 
in platelet counts in chimpanzees and humans.11-14 
Ex vivo experiments with platelets from humans 
and in vivo studies of healthy subjects have shown 
that treatment with eltrombopag does not ad-
versely affect platelet function.15,16 Eltrombopag 
has also been shown to increase platelet counts 
in a dose-dependent manner in patients with 
chronic immune thrombocytopenic purpura.17
In this phase 2 study, we assessed whether the 
use of eltrombopag can increase platelet counts 
in patients with thrombocytopenia associated 
with cirrhosis due to chronic HCV infection. The 
safety and adverse-event profiles of eltrombopag 
were also evaluated.
Me thods
Patients
Patients were enrolled from 22 centers in the 
United States and Europe. Eligible patients were 
18 years of age or older and had chronic HCV 
infection (defined as the presence of anti-HCV 
antibodies and detectable serum HCV RNA levels, 
as determined with the use of a clinically avail-
able assay chosen by the investigator), compensat-
ed liver disease, and thrombocytopenia (defined 
as a platelet count of 20,000 to <70,000 per cubic 
millimeter). Patients were also required to have a 
liver-biopsy specimen indicative of cirrhosis, radio-
graphic evidence of cirrhosis, or endoscopic evi-
dence of portal hypertension. Patients were ex-
cluded if they were pregnant, had a history of 
thrombosis, or were coinfected with the human 
immunodeficiency virus or the hepatitis B virus.
Our study was approved by the institutional 
review board or ethics committee at each partici-
pating center and was conducted in accordance 
with the provisions of the Declaration of Helsinki, 
Good Clinical Practice guidelines, and local laws 
and regulations. All patients provided written in-
formed consent.
Study Design and Organization
Our study was an international, multicenter, dou-
ble-blind, randomized, placebo-controlled, phase 2 
trial covering a range of doses of eltrombopag. 
After meeting the eligibility criteria, patients were 
randomly assigned to study groups in a 1:1:1:1 
ratio with the use of permuted-block randomiza-
tion and a block size of four. The random assign-
ment was stratified according to the baseline plate-
let count (20,000 to <50,000 per cubic millimeter 
vs. 50,000 to <70,000 per cubic millimeter). Pa-
tients were assigned to an eltrombopag group or 
the placebo group by means of central randomiza-
tion, which was independent of the study centers 
and involved an interactive voice system. In the 
initial treatment phase, patients received either el-
trombopag tablets, once daily, at a dose of 30 mg, 
50 mg, or 75 mg or matching placebo, once daily, 
for 4 weeks (Fig. 1). Hematologic, biochemical, 
and other safety assessments were performed 
weekly. Treatment with eltrombopag was inter-
rupted if the platelet count was 200,000 or more 
per cubic millimeter; treatment was then reinstat-
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Initial Treatment Phase
Antiviral Treatment Phase
(peginterferon+eltrombopag
or placebo)
74 Patients were randomly assigned
to a study group
18 Received placebo
14 Received 30 mg
of eltrombopag
19 Received 50 mg
of eltrombopag
23 Received 75 mg
of eltrombopag
4 Received
peginterferon
10 Received
peginterferon
14 Received
peginterferon
21 Received
peginterferon
2 Did not receive
 peginterferon
1 Owing to lack 
of efficacy
1 For unspecified
reasons
5 Did not receive
 peginterferon
2 For personal
reasons
2 Owing to lack 
of efficacy
1 For unspecified
reasons
4 Did not receive 
 peginterferon
1 Owing to an
adverse event
2 For personal
reasons
1 For unspecified
reasons
14 Did not receive 
 peginterferon
2 For personal
reasons
7 Owing to lack 
of efficacy
5 For unspecified
reasons
1 Completed 12 wk
of peginterferon therapy
5 Completed 12 wk
of peginterferon therapy
10 Completed 12 wk
of peginterferon therapy
15 Completed 12 wk
of peginterferon therapy
5 Did not complete
12 wk of peg-
interferon
therapy
2 Owing to an
adverse event
1 Owing to loss 
to follow-up
1 For personal
reasons
1 For unspecified
reasons
4 Did not complete
12 wk of peg-
interferon
therapy
1 Owing to an
adverse event
1 Owing to lack 
of efficacy
1 For personal
reasons
1 For unspecified
reasons
6 Did not complete
12 wk of peg-
interferon
therapy
1 Owing to an
adverse event
1 Owing to loss 
to follow-up
4 For unspecified
reasons
3 Did not complete
12 wk of peg-
interferon
therapy
1 Owing to lack 
of efficacy
2 For unspecified
reasons
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Figure 1. Randomization and Follow-up of the Study Patients.
In the initial treatment phase, patients received eltrombopag (30, 50, or 75 mg) or placebo daily for 4 weeks. Hematologic and safety 
 assessments were performed weekly during this phase. After 4 weeks, antiviral therapy for 12 weeks with peginterferon and ribavirin  
was added in patients with adequate platelet counts (≥70,000 per cubic millimeter for peginterferon alfa-2a or ≥100,000 per cubic milli-
meter for peginterferon alfa-2b), followed by a 4-week follow-up period. Five of the 74 patients (7%) were excluded from the primary 
analysis owing to baseline platelet counts of 70,000 or more per cubic millimeter (2 patients receiving placebo, 2 receiving 50 mg of 
 eltrombopag, and 1 receiving 75 mg of eltrombopag). Two patients in the placebo group who received peginterferon antiviral therapy  
did so in error, since their platelet counts were less than 70,000 per cubic millimeter. During the antiviral treatment phase, the platelet 
count was less than 50,000 per cubic millimeter in four patients receiving placebo, five receiving 30 mg of eltrombopag, four receiving 
50 mg, and three receiving 75 mg. All patients in the eltrombopag groups in whom peginterferon was initiated had baseline platelet 
counts of more than 100,000 per cubic millimeter at the time of initiation. The known reasons for the lack of initiation of interferon anti-
viral therapy or lack of its completion were recorded by the investigator when the patient left the study. Lack of efficacy was defined as  
a platelet count that was not high enough for the initiation or continuation of antiviral therapy. Adverse events were defined as any un-
toward medical occurrence temporarily associated with the use of the study drug, whether or not it was considered to be related to the 
study drug.
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ed on an individual basis, generally when platelet 
counts returned to 100,000 or less per cubic mil-
limeter.
Patients who completed the initial treatment 
phase were eligible for antiviral treatment if they 
had attained a predefined platelet count: 70,000 
or more per cubic millimeter for the use of peg-
interferon alfa-2a (Pegasys, Roche) or 100,000 or 
more per cubic millimeter for the use of peginter-
feron alfa-2b (Peg-Intron, Schering-Plough). The 
choice of interferon was not dictated by the proto-
col but rather was at the investigator’s discretion.
In this antiviral treatment phase, peginterferon 
(180 μg of peginterferon alfa-2a per week or 1.5 
μg of peginterferon alfa-2b per kilogram of body 
weight per week) and ribavirin (1000 to 1200 mg 
per day for patients receiving peginterferon alfa-
2a and 800 mg per day for those receiving pegin-
terferon alfa-2b) were administered for 8 weeks 
concomitantly with eltrombopag or placebo. Once 
additional preclinical safety data were available, 
the protocol was amended to extend this phase to 
12 weeks, at which time eltrombopag was stopped 
and antiviral therapy was continued at the inves-
tigator’s discretion. A follow-up visit was sched-
uled for 4 weeks after the last dose of eltrom-
bopag or placebo had been received. Throughout 
the antiviral treatment phase, in accordance 
with the product labels for these approved thera-
pies, the dose of peginterferon alfa-2a was re-
duced by half if the platelet count had decreased 
to 25,000 to 50,000 per cubic millimeter and was 
discontinued altogether if the platelet count was 
below 25,000 per cubic millimeter. The dose of 
peginterferon alfa-2b was reduced by half if the 
platelet count had decreased to 50,000 to 80,000 
per cubic millimeter and was discontinued alto-
gether if the platelet count was less than 50,000 
per cubic millimeter.
An independent data monitoring committee 
was established to review data during the study. 
A separate independent committee reviewed all 
ophthalmic evaluations, because ocular findings 
in preclinical studies of immature rodents indicat-
ed a risk of cataract formation.
The sponsor, GlaxoSmithKline, and the aca-
demic principal investigator designed the study, 
developed the protocol, and prepared the first and 
subsequent drafts of the manuscript, with input 
from participating academic investigators. The 
sponsor and the academic principal investigator 
held and analyzed the data. Decisions related to 
the content of the final draft of the manuscript 
were made by the academic principal investigator 
in consultation with all coauthors. All authors, 
four of whom are employees of GlaxoSmithKline, 
had access to the data and contributed to the writ-
ing of the manuscript. The academic principal in-
vestigator vouches for the completeness and ac-
curacy of this article.
Statistical Analysis
The primary efficacy end point was an increase in 
the platelet count from the baseline value (20,000 
to <70,000 per cubic millimeter) to 100,000 or 
more per cubic millimeter after the 4-week initial 
treatment phase. Secondary end points included 
those related to safety, tolerability, and the ability 
to continue peginterferon therapy during the anti-
viral treatment phase. The analyses included all 
patients who were randomly assigned to a study 
group and who received at least one dose of the 
study medication. In the analysis of the primary 
end point, however, data for 5 of the 74 patients 
(7%) who entered the study but whose baseline 
platelet count was 70,000 or more per cubic milli-
meter were excluded; missing data were imputed 
with the use of the last-observation-carried-for-
ward approach.
We planned to enroll 160 patients in the study, 
with 40 patients randomly assigned to each study 
group. We estimated the number of patients as-
suming a rate of response of 20% in the placebo 
group and 60% in the three active treatment 
groups. The power of our study to detect this 
anticipated treatment effect was 90% at an overall 
two-sided level of significance of 5%. The primary 
end point was analyzed with the use of multiple 
logistic-regression analysis. Each of the three el-
trombopag groups was compared with the place-
bo group by means of a closed testing procedure. 
We tested the global null hypothesis of no sig-
nificant difference among the four study groups 
and, if this global hypothesis was rejected, the 
null hypothesis of no significant difference be-
tween the placebo group and each eltrombopag 
group, with testing performed in the predeter-
mined order of the highest dose (75 mg) to the 
lowest dose (30 mg). The sequential testing was 
continued until the null hypothesis could not be 
rejected.
The study was originally planned to be per-
formed without interim analyses, except for a 
blinded review by the independent data monitor-
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ing committee of the safety and adverse-event 
profiles after 40 patients had completed the ini-
tial treatment phase. A subsequent amendment 
to the protocol stipulated the performance of for-
mal interim analyses of efficacy data from the 
initial treatment phase.
The criterion for stopping the study early was 
a two-sided P value no greater than 0.0001, based 
on the O’Brien–Fleming adjustment for a group-
sequential design, from an interim analysis of the 
efficacy data.18 The criterion was not met in the 
first interim analysis but was met in the second 
interim analysis (overall comparison for the four 
study groups, P<0.0001; 30 mg of eltrombopag vs. 
placebo, P = 0.00067; 50 mg of eltrombopag vs. 
placebo, P = 0.00015; and 75 mg of eltrombopag 
vs. placebo, P<0.0001).
R esult s
Characteristics of the Patients
Between April 5, 2005, and October 20, 2006, a 
total of 74 patients were randomly assigned to a 
study group and received the study drug or pla-
cebo (Fig. 1): 18 patients received placebo, 14 re-
ceived 30 mg of eltrombopag, 19 received 50 mg 
of eltrombopag, and 23 received 75 mg of eltrom-
bopag. Since the 74 patients were distributed across 
22 sites, some sites did not use a complete block, 
which caused a slight imbalance in the numbers 
of patients assigned to the four groups. The demo-
graphic and baseline clinical characteristics of the 
study groups were well balanced (Table 1). The 
median age was 51 years (range, 30 to 74), and 
more than two thirds of the patients were men.
Table 1. Baseline Characteristics of the Patients.*
Characteristic Eltrombopag Placebo (N = 18) All (N = 74)
30 mg (N = 14) 50 mg (N = 19) 75 mg (N = 23)
Age — yr
Median 56 50 51 52 51
Range 43–74 30–72 38–60 41–71 30–74
Sex — no. (%)
Male 10 (71) 12 (63) 19 (83) 11 (61) 52 (70)
Female 4 (29) 7 (37) 4 (17) 7 (39) 22 (30)
Race — no. (%)†
Black 0 2 (11) 1 (4) 1 (6) 4 (5)
Asian 0 1 (5) 0 1 (6) 2 (3)
White 13 (93) 16 (84) 22 (96) 16 (89) 67 (91)
Platelet count 
Median — per mm3 59,000 52,000 54,000 55,000 55,000
Range — per mm3 34,000–94,000 26,000–66,000 28,000–75,000 27,000–75,000 26,000–94,000
20,000 to <50,000/mm3 — no. (%) 5 (36) 7 (37) 8 (35) 6 (33) 26 (35)
≥50,000 to <70,000/mm3 — no. (%) 7 (50) 12 (63) 13 (57) 11 (61) 43 (58)
≥70,000/mm3 — no. (%) 2 (14) 0 2 (9) 1 (6) 5 (7)
HCV genotype — no. (%)
1 or 4 10 (71) 11 (58) 14 (61) 10 (56) 45 (61)
2 or 3 4 (29) 8 (42) 8 (35) 7 (39) 27 (36)
Unknown 0 0 1 (4) 1 (6) 2 (3)
Albumin — g/liter 35.8±6.8 33.8±4.9 36.6±5.7 36.4±5.8 35.7±5.7
Alanine aminotransferase — IU/liter 120.6±51.4 117.8±67.5 117.0±69.3 120.5±70.7 118.8±64.2
Aspartate aminotransferase — IU/liter 123.3±68.1 127.4±67.3 128.6±104.1 129.5±72.8 127.5±79.2
Total bilirubin — µmol/liter 25.3±11.5 25.1±14.1 24.9±16.3 27.7±14.0 25.7±14.4
* Plus–minus values are means ±SD. There were no significant differences in characteristics between the study groups. HCV denotes hepati-
tis C virus. To convert values for total bilirubin to milligrams per deciliter, divide by 17.1.
† Race was self-reported; data were not available for one patient.
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 357;22 www.nejm.org november 29, 20072232
The median baseline platelet count was 55,000 
per cubic millimeter (range, 26,000 to 94,000). 
The baseline platelet count was 20,000 to less 
than 50,000 per cubic millimeter in 35% of pa-
tients (26 of 74) and 50,000 to less than 70,000 
per cubic millimeter in 58% (43 of 74) (Table 1). 
Seven percent of patients (5 of 74) who were suc-
cessfully screened had baseline platelet counts of 
70,000 or more per cubic millimeter just before 
administration of the study drug, which was con-
sidered a violation of the protocol. Therefore, the 
data for these five patients were excluded from 
the analysis of the primary efficacy end point, 
but they were included in the safety analysis be-
cause the patients received the study drug.
Efficacy
Initial Treatment Phase
The receipt of eltrombopag increased platelet 
counts to 100,000 or more per cubic millimeter at 
week 4, in a dose-dependent manner (P<0.001 for 
overall treatment effect) (Table 2). The effect of 
each dose of eltrombopag was significant (P<0.001), 
as compared with the effect of placebo. No patient 
in the placebo group had an increase in the plate-
let count to 100,000 or more per cubic millimeter 
after 4 weeks. The results for the primary end 
point based on the observed data only (i.e., those 
obtained without the application of the last-obser-
vation-carried-forward approach) were similar to 
the results when the last-observation-carried-for-
Table 2. Median Platelet Counts at the End of the Initial Treatment Phase and the End of the Antiviral Treatment Phase.*
Variable Eltrombopag Placebo (N = 18)
30 mg (N = 14) 50 mg (N = 19) 75 mg (N = 23)
End of initial treatment phase
Platelet count
No. of patients with data 11 16 22 14
Median — per mm3 125,000 212,000 204,000 53,000
Range — per mm3 40,000 to 214,000 47,000 to 599,000 78,000 to 527,000 34,000 to 74,000
Change from baseline
No. of patients with data 12 16 22 14
Median — per mm3 74,000 152,000 151,000 −3,000
Range — per mm3 6,000 to 155,000 10,000 to 540,000 45,000 to 473,000 −22,000 to 13,000
≥100,000/mm3 — no. of responders/total no.  
of patients who could be evaluated (%)
9/12 (75) 15/19 (79) 20/21 (95) 0/17
≥200,000/mm3 — no. of responders/total no.  
of patients who could be evaluated (%)
3/12 (25) 9/19 (47) 11/21 (52) 0/17
End of antiviral treatment phase
Platelet count
No. of patients with data 2 7 8 1
Median — per mm3 106,000 100,000 92,000 39,000
Range — per mm3 43,000 to 164,000 46,000 to 156,000 38,000 to 245,000 39,000 to 39,000
Change from baseline — per mm3
Median 31,000 54,000 31,000 −25,000
Range −18,000 to 122,000 8000 to 97,000 −23,000 to 191,000 −25,000 to −25,000
* Data were not available for some patients because of withdrawal from the study before week 4 or for other reasons. Patients who could  
be evaluated were those whose data were included in the last-observation-carried-forward analysis in the intention-to-treat population and 
excluded those with a platelet count of less than 20,000 per cubic millimeter or 70,000 or more per cubic milliliter at baseline or those for 
whom the platelet count was unknown during the antiviral treatment phase. The overall P value for the treatment effect at the end of the 
initial treatment phase was less than 0.001, as were the P values for the comparison of each eltrombopag group with the placebo group 
with respect to the percentages of patients with platelet counts of 100,000 or more per cubic millimeter at the end of the initial treatment 
phase.
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ward approach was used. Between 25 and 52% of 
patients receiving eltrombopag (primarily those re-
ceiving 50-mg or 75-mg doses daily) had platelet 
counts of 200,000 or more per cubic millimeter at 
any time during the initial treatment phase. Treat-
ment with eltrombopag was interrupted in these 
patients until their platelet counts decreased to 
100,000 or fewer per cubic millimeter.
Antiviral Treatment Phase
Overall, two thirds of the patients (49 of 74) pro-
ceeded to the antiviral treatment phase: 4 of the 
18 patients (22%) receiving placebo and 10 of the 
14 (71%), 14 of the 19 (74%), and 21 of the 23 (91%) 
receiving 30 mg, 50 mg, and 75 mg of eltrom-
bopag, respectively (Fig. 1). Of these 49 patients, 
48 had a platelet count that met the prespecified 
threshold for entry into the antiviral treatment 
phase (≥70,000 per cubic millimeter for the use 
of peginterferon alfa-2a or ≥100,000 per cubic 
millimeter for the use of peginterferon alfa-2b), 
and therefore peginterferon-based therapy could 
be initiated (Fig. 1).
On an intention-to-treat basis, the first 12 
weeks of antiviral therapy were completed by 5 of 
14 patients receiving 30 mg of eltrombopag 
(36%), 10 of 19 receiving 50 mg (53%), and 15 of 
23 receiving 75 mg (65%), as compared with 1 of 
18 patients (6%) in the placebo group (Fig. 2). 
Platelet counts in all eltrombopag groups de-
creased during the antiviral treatment phase, 
despite continued treatment with eltrombopag, 
but remained consistently above baseline values, 
with a nadir of more than 50,000 per cubic milli-
meter (Table 2 and Fig. 2). Among the patients 
who completed the 12-week antiviral treatment 
phase and for whom platelet counts were avail-
able, a platelet count greater than the baseline 
value was maintained after completion of the 
antiviral treatment phase in 0 of 1 patient receiv-
ing placebo, 4 of 5 receiving 30 mg of eltrombo-
pag, 4 of 5 receiving 50 mg of eltrombopag, and 
10 of 12 receiving 75 mg of eltrombopag.
At all time points during the antiviral treat-
ment phase, platelet counts in all three eltrombo-
pag groups were higher than those in the place-
bo group and remained higher than the level at 
which a reduction in the peginterferon dose is 
recommended (<50,000 per cubic millimeter). In 
the group receiving 75 mg of eltrombopag, 18 of 
21 patients had platelet counts of 50,000 or more 
per cubic millimeter during this phase. No pa-
tient in the placebo group had a platelet count 
this high while receiving antiviral therapy. In the 
initial or antiviral treatment phase, platelet counts 
exceeded the protocol-specified upper limit of 
200,000 per cubic millimeter in at least one visit 
in 4 of 14 patients (29%), 9 of 19 (47%), and 16 of 
23 (70%) in the groups receiving 30 mg of eltrom-
bopag, 50 mg of eltrombopag, and 75 mg of 
eltrombopag, respectively, necessitating a tempo-
rary interruption in eltrombopag therapy.
Safety
During the 4-week initial treatment phase, head-
ache was reported in 36%, 16%, and 17% of pa-
tients who received 30 mg of eltrombopag, 50 mg 
of eltrombopag, and 75 mg of eltrombopag, respec-
tively, as well as in 17% of patients who received 
placebo (Table 3). Other common adverse events 
in the three eltrombopag groups were dry mouth, 
abdominal pain, and nausea.
During the subsequent antiviral treatment 
phase, the incidence of adverse events was simi-
lar in all three eltrombopag groups. The adverse 
events most commonly reported during this phase 
were influenza-like illness, fatigue, chills, and 
headache, all of which are known side effects of 
interferon-based therapy.19,20
Drug-related adverse events were reported for 
five patients receiving 30 mg of eltrombopag 
(36%), eight receiving 50 mg (42%), and eight re-
ceiving 75 mg (35%), as compared with three pa-
tients (17%) in the placebo group. The most fre-
quent drug-related adverse events (all of low-grade 
severity) were dry mouth, headache, and nausea. 
After treatment had been discontinued, thrombo-
cytopenia occurred in one patient receiving 30 mg 
of eltrombopag, decreased visual acuity occurred 
in another receiving 30 mg of eltrombopag, and 
petechiae occurred in one patient receiving 75 mg 
of eltrombopag.
During the entire study, 62 patients reported 
adverse events and 7 reported serious adverse 
events. These serious events included ascites (in 
the group receiving 30 mg of eltrombopag), which 
subsequently resolved, and retinal exudates (in 
the group receiving 75 mg of eltrombopag), which 
did not resolve and which were deemed by the 
investigator to be unrelated to treatment with 
eltrombopag. Thrombocytopenia in one patient 
receiving 30 mg of eltrombopag and myositis in 
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
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one patient receiving 50 mg of eltrombopag were 
resolving at the end of the study. The thrombo-
cytopenia occurred after eltrombopag therapy had 
been discontinued and peginterferon administra-
tion had begun; the platelet count fell below the 
patient’s baseline count, and the event was con-
sidered by the investigator to be related to the 
study drug. One patient in the placebo group had 
two reported serious adverse events, abdominal 
pain and renal failure, and subsequently died. 
Adverse events led to the withdrawal of three 
patients receiving 30 mg of eltrombopag (owing 
to upper abdominal pain and ascites), one patient 
receiving 50 mg of eltrombopag (owing to neutro-
penia), and one patient receiving 75 mg of eltrom-
bopag (owing to retinal exudates).
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Figure 2. Median Platelet Counts and Percentages of Patients Who Completed the 12-Week Antiviral Treatment Phase.
During the initial treatment phase, in which patients received eltrombopag or placebo, the median platelet count for 
each eltrombopag group was increased relative to the baseline value in a dose-dependent manner (Panel A). Counts 
reached a maximum at week 4, after which antiviral therapy was initiated while the administration of eltrombopag or 
placebo was continued. As expected, because of the marrow-suppressive effects of peginterferon, counts declined 
during the antiviral treatment phase and reached a nadir. However, platelet counts in the active-treatment groups 
remained higher than those in the placebo group and those at baseline. I bars indicate the minimum and maximum 
values. Panel B shows the percentages of all patients randomly assigned to each group who completed 12 weeks of 
antiviral therapy.
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Discussion
Thrombocytopenia in patients with cirrhosis due 
to HCV can prevent or limit antiviral treatment, 
but there is little information concerning the eli-
gibility for treatment of patients with platelet 
counts of less than 50,000 per cubic millimeter. 
In our study, 30 of 45 patients who had had a 
response to eltrombopag, with a rise in the plate-
let count to 70,000 or more per cubic millimeter 
(or ≥100,000 per cubic millimeter) during the ini-
tial treatment phase, completed the first 12 weeks 
of antiviral treatment with peginterferon, during 
which time the use of eltrombopag was contin-
ued; specifically, 65% of those receiving 75 mg of 
eltrombopag and 53% of those receiving 50 mg 
of eltrombopag completed the first 12 weeks of 
the treatment.
The most common side effects of eltrombopag 
during the initial treatment phase were head-
ache, dry mouth, abdominal pain, and nausea; 
these effects were of insufficient severity to re-
quire discontinuation of the drug. In this small 
and therefore underpowered study, we did not 
find evidence of a dose–response relation with 
respect to the occurrence of adverse events in the 
antiviral treatment phase, during which the re-
ported side effects were consistent with those 
associated with interferon-based therapy.
During the initial treatment phase, significant 
increases in platelet counts were observed in each 
of the three eltrombopag groups as compared 
with the placebo group. The primary end point 
(a platelet count ≥100,000 per cubic millimeter at 
week 4) was met in 75 to 95% of patients in the 
eltrombopag groups, in a dose-dependent man-
Table 3. Most Common Adverse Events during the Initial Treatment Phase and the Antiviral Treatment Phase.*
Event Eltrombopag Placebo (N = 18)
30 mg (N = 14) 50 mg (N = 19) 75 mg (N = 23)
number of events (percent)
Initial treatment phase
Any 11 (79) 10 (53) 13 (57) 10 (56)
Headache 5 (36) 3 (16) 4 (17) 3 (17)
Dry mouth 2 (14) 2 (11) 2 (9) 1 (6)
Upper abdominal pain 2 (14) 2 (11) 0 0
Nausea 1 (7) 2 (11) 1 (4) 0
Antiviral treatment phase
Any 9 (64) 13 (68) 17 (74) 3 (17)
Influenza-like illness 4 (29) 5 (26) 8 (35) 1 (6)
Fatigue 4 (29) 5 (26) 5 (22) 1 (6)
Chills 0 6 (32) 2 (9) 1 (6)
Headache 3 (21) 3 (16) 3 (13) 0
Arthralgia 3 (21) 1 (5) 2 (9) 1 (6)
Depression 2 (14) 1 (5) 4 (17) 0
Myalgia 3 (21) 2 (11) 2 (9) 0
Nausea 3 (21) 3 (16) 1 (4) 0
Anemia 2 (14) 2 (11) 2 (9) 0
Pyrexia 1 (7) 3 (16) 2 (9) 0
Diarrhea 0 1 (5) 3 (13) 1 (6)
Irritability 2 (14) 0 1 (4) 1 (6)
Pruritus 1 (7) 2 (11) 0 1 (6)
Rash 0 3 (16) 1 (4) 0
* The adverse events listed are those that occurred in more than 3% of patients in any group.
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ner. During the subsequent antiviral phase, plate-
let counts decreased, perhaps owing to the anti-
platelet effect of peginterferon; nevertheless, 
platelet counts remained consistently above base-
line levels. These results require confirmation in 
phase 3 trials involving standard-duration courses 
of peginterferon and ribavirin.
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